Additional file 1 of Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure

Abstract

Additional file 1: Table S1. Clinical characteristics of enrolled subjects from the COSSH prospective multicenter cohort. Table S2. Clinical characteristics of ACLF patients in the ELISA validation group from the COSSH prospective multicenter cohort. Table S3. Primers used for real-time PCR. Table S4. Antibodies used for immunoblotting and immunohistochemistry. Table S5. Clinical characteristics of ACLF patients with different THBS1 relative expression in the validation group. Table S6. Clinical characteristics of ACLF patients in the low-risk group and high-risk group of the ELISA validation cohort. Table S7. The enriched biological processes for the top 200 genes which were both differentially expressed in the comparisons of ACLF vs. LC and ACLF vs. NC. Table S8. The immune-related biological processes for top 200 DEGs which were both differentially expressed in the comparisons of ACLF vs. LC and ACLF vs. NC. Table S9. The apoptosis-related biological processes for top 200 DEGs which were both differentially expressed in the comparisons of ACLF vs. LC and ACLF vs. NC